Kiromic BioPharma announced that on September 12, it received formal notice from the NASDAQ Stock Market that the company’s common stock has been suspended from trading on the Nasdaq Capital Market effective September 14, due to failure to demonstrate compliance with Listing Rule 5550(b). The company’s common stock will be quoted on the Pink Sheets platform operated by OTC Markets and will commence trading on September 14 at the market open under the “KRBP” ticker symbol while it pursues an uplisting to the OTCQB exchange. While the reporting requirements are different on the OTC Pink Sheets, the company will continue to file regular financial statements and provide updates consistent with Nasdaq requirements and past practices.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
